TherapeuticsMD (NASDAQ:TXMD) Trading Down 4% – Here’s What Happened

TherapeuticsMD, Inc. (NASDAQ:TXMD)’s share price traded down 4% during mid-day trading on Tuesday . The company traded as low as $2.26 and last traded at $2.38. 32,296 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 120,059 shares. The stock had previously closed at $2.48.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of TherapeuticsMD from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, January 12th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has an average rating of “Hold”.

TherapeuticsMD Stock Down 4.0%

The company has a market capitalization of $27.54 million, a P/E ratio of -238.00 and a beta of 0.52. The business has a 50 day simple moving average of $2.00 and a 200-day simple moving average of $1.49.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Wednesday, November 12th. The company reported $0.01 earnings per share for the quarter. The business had revenue of $0.78 million for the quarter. TherapeuticsMD had a net margin of 10.80% and a return on equity of 0.27%.

Hedge Funds Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Citadel Advisors LLC raised its holdings in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 125.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,273 shares of the company’s stock after acquiring an additional 19,073 shares during the period. Citadel Advisors LLC owned approximately 0.30% of TherapeuticsMD worth $36,000 as of its most recent SEC filing. 30.74% of the stock is owned by institutional investors and hedge funds.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.